1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Immunoassay Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising chronic and infectious diseases and benefits of early diagnosis
5.1.1.2. Growing usage of immunoassay in the food & beverage sector
5.1.1.3. Emerging application of multiplex detection immunoassay technique in drug development
5.1.2. Restraints
5.1.2.1. Cross-reactivity issues associated with immunoassay
5.1.3. Opportunities
5.1.3.1. Technological advancements in the number of automated instruments and equipment associated with immunoassay
5.1.3.2. High potential of immunoassay in environment monitoring
5.1.4. Challenges
5.1.4.1. Issues with assay validation due to variations in sample quality and reagent performance
5.2. Market Segmentation Analysis
5.2.1. Product: Development of novel immunoassay kits for diagnostics of infectious and autoimmune diseases
5.2.2. Technology: Utilization of enzyme-linked immunosorbent assay technology for food allergies and drugs of abuse treatment
5.2.3. Specimen: Emergence of saliva diagnostics due to its non-invasive collection methods
5.2.4. Indication: Optimization within immunoassay technologies to cater growing need across infectious disease
5.2.5. End User: Rising demand for immunoassay across emergency care, intensive care units, and outpatient clinics
5.3. Market Trend Analysis
5.3.1. Introduction of novel sustainable immunoassays with government funding to scale up of immunoassays in the Americas
5.3.2. Prevalence of infectious and autoimmune diseases, and rising need for efficient healthcare solution in the Asia-Pacific region
5.3.3. Increasing support by government to expand adoption of immunoassay coupled with strong presence of healthcare companies in EMEA region
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
6. Immunoassay Market, by Product
6.1. Introduction
6.2. Analyzer
6.3. Consumables
6.4.1. Assay Kits
6.4.2. Microwell Plates & Tubes
6.4.3. Reagents
7. Immunoassay Market, by Technology
7.1. Introduction
7.2. Chemiluminescence Immunoassay
7.3. Enzyme-linked Immunosorbent Assay
7.4. Fluoroimmunoassay
7.5. Radioimmunoassay
7.6. Rapid Diagnostic Tests (RDTs)/Lateral Flow Immunoassay
8. Immunoassay Market, by Specimen
8.1. Introduction
8.2. Blood
8.3. Saliva
8.4. Urine
9. Immunoassay Market, by Indication
9.1. Introduction
9.2. Cardiology
9.3. Endocrinology
9.4. Infectious Disease
9.5. Oncology
9.6. Orthopedics
10. Immunoassay Market, by End User
10.1. Introduction
10.2. Blood Banks
10.3. Diagnostics Laboratories
10.4. Food & Beverage Companies
10.5. Hospitals
10.6. Pharmaceutical Companies & CROs
10.7. Research & Academic Laboratories
11. Americas Immunoassay Market
11.1. Introduction
11.2. Argentina
11.3. Brazil
11.4. Canada
11.5. Mexico
11.6. United States
12. Asia-Pacific Immunoassay Market
12.1. Introduction
12.2. Australia
12.3. China
12.4. India
12.5. Indonesia
12.6. Japan
12.7. Malaysia
12.8. Philippines
12.9. Singapore
12.10. South Korea
12.11. Taiwan
12.12. Thailand
12.13. Vietnam
13. Europe, Middle East & Africa Immunoassay Market
13.1. Introduction
13.2. Denmark
13.3. Egypt
13.4. Finland
13.5. France
13.6. Germany
13.7. Israel
13.8. Italy
13.9. Netherlands
13.10. Nigeria
13.11. Norway
13.12. Poland
13.13. Qatar
13.14. Russia
13.15. Saudi Arabia
13.16. South Africa
13.17. Spain
13.18. Sweden
13.19. Switzerland
13.20. Turkey
13.21. United Arab Emirates
13.22. United Kingdom
14. Competitive Landscape
14.1. FPNV Positioning Matrix
14.2. Market Share Analysis, By Key Player
14.3. Competitive Scenario Analysis, By Key Player
14.3.1. Merger & Acquisition
14.3.1.1. Thermo Fisher to Acquire Olink for USD 3.1 billion, Expanding Proteomics Presence
14.3.1.2. Mindray Has Agreed to Acquire 75% Stake in Germany-Based DiaSys Diagnostic Systems GmbH
14.3.1.3. MakatiMed First PH and ASEAN Hospital to Acquire Atellica VTLi Patient-Side Immunoassay Analyzer
14.3.2. Agreement, Collaboration, & Partnership
14.3.2.1. Fujirebio and Sysmex to Collaborate On Development of Unique Immunoassays
14.3.2.2. Beckman Coulter and Fujirebio Partner to Bolster Access to Patient-friendly, Blood-based Alzheimer’s Disease Test
14.3.3. New Product Launch & Enhancement
14.3.3.1. Fapon Rolls Out New Chemiluminescence Immunoassay System
14.3.3.2. Beckman Coulter’s DxI 9000 Immunoassay Analyzer with Increased Assay Development Sensitivity Makes First North American Appearance at 2023 AACC
14.3.3.3. SGS Offers Enhanced Automated Immunoassay Testing at Poitiers Laboratory
14.3.4. Investment & Funding
14.3.4.1. CVC Fund “Shimadzu Future Innovation Fund” has Invested in IMMUNOSENS Co., Ltd., Developing Immunoassay Technology.
14.3.5. Award, Recognition, & Expansion
14.3.5.1. QuidelOrtho Receives De Novo FDA Authorization for Sofia 2 SARS Antigen+ FIA
14.3.5.2. Siemens launches Centre of Excellence for Immunoassay Instrument R&D
15. Competitive Portfolio
15.1. Key Company Profiles
15.1.1. Abbott Laboratories
15.1.2. Agilent Technologies Inc.
15.1.3. Almac Group Limited
15.1.4. ANP Technologies, Inc.
15.1.5. Autobio Diagnostics Co., Ltd.
15.1.6. Becton, Dickinson, and Company
15.1.7. Bio-Rad Laboratories, Inc.
15.1.8. Bio-Techne Corporation
15.1.9. BioLegend, Inc.
15.1.10. bioMérieux S.A.
15.1.11. Biosurfit SA
15.1.12. Boditech Med Inc.
15.1.13. Charles River Laboratories International, Inc.
15.1.14. Danaher Corporation
15.1.15. Diasorin S.p.A.
15.1.16. Dynex Technologies, Inc.
15.1.17. Epitope Diagnostics Inc.
15.1.18. F. Hoffmann-La Roche Ltd.
15.1.19. Fapon Biotech Inc.
15.1.20. Gyros Protein Technologies AB
15.1.21. H.U. Group Holdings Inc.
15.1.22. J. Mitra & Co. Pvt. Ltd.
15.1.23. Kamiya Biomedical Company
15.1.24. Koninklijke Philips N.V.
15.1.25. Merck KGaA
15.1.26. MiCo BioMed, Inc.
15.1.27. NanoEntek
15.1.28. Nanōmix, Inc.
15.1.29. OPKO Health, Inc.
15.1.30. PerkinElmer, Inc.
15.1.31. Promega Corporation
15.1.32. QIAGEN N.V.
15.1.33. Quanterix Corporation
15.1.34. QuidelOrtho Corporation
15.1.35. Randox Laboratories Ltd.
15.1.36. Shenzhen Micropoint Biotechnologies Co., Ltd.
15.1.37. Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
15.1.38. Siemens Healthineers AG
15.1.39. Sysmex Corporation
15.1.40. Tecan Trading AG
15.1.41. Thermo Fisher Scientific Inc.
15.1.42. Tosoh Corporation
15.1.43. WAK-Chemie Medical GmbH
15.1.44. Zoetis Inc.
15.1.45. Zybio Inc.
15.2. Key Product Portfolio
16. Appendix
16.1. Discussion Guide
16.2. License & Pricing